% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • checksurshorts checksurshorts Jul 11, 2014 5:07 PM Flag

    New 8k

    On July 8, 2014, Insmed Incorporated (the “Company”) entered into a Commercialization Agreement (the “Agreement”) with PARI Pharma GmbH (“PARI”) for the manufacture and supply of eFlow nebulizer systems and related accessories (the “Device”) as optimized for use with the Company’s proprietary liposomal amikacin for inhalation. The Agreement has an initial term of fifteen (15) years from the first commercial sale of the Device (the “Initial Term”). The term of the Agreement may be extended by the Company for an additional five (5) years by providing written notice to PARI at the least one (1) year prior to the expiration of the Initial Term. Notwithstanding the foregoing, the parties have certain rights and obligations under the Agreement prior to the commencement of the Initial Term. The Agreement allows for termination by either party upon the occurrence of certain events, including (i) the material breach by the other party of any provision of the Agreement, (ii) the default or bankruptcy of the other party, or (iii) upon termination by the Company of the License Agreement between the parties.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
12.90+0.22(+1.74%)Aug 25 4:00 PMEDT